GLOSSARY
Clinical trial terms used in this CRO RFI guide
- Phase IIb / III trial
- Late-stage efficacy and confirmatory clinical trials in patients prior to regulatory submission (NDA/BLA). Shortlisted CROs use varying labels (such as IQVIA’s “Phase IIb/III Trials”, Parexel’s Phase IIb-IV, or Precision’s Phase 2b-4 pivotal). IQVIA record.
- Full-Service Outsourcing (FSO) vs. Functional Service Provider (FSP)
- In FSO, one CRO manages end-to-end trial operations under a unified contract. In FSP, the sponsor retains overall study control and hires specialized functional teams (e.g., biostatistics, monitoring, data management).
- Accellacare in-home service
- ICON’s named decentralized/in-home clinical visit service (“all phases”). Vendor page claim tied to Accellacare in-home services; does not establish general CRO phase experience, sponsor-specific delivery or outcomes. ICON record.
- Trial rescue / transition study
- Transferring an ongoing clinical trial from one CRO to another due to enrollment delays, quality issues, or M&A disruption. Reviewed statements include Worldwide Clinical Trials (“Phase I-IV trial execution, RWE, and Transition Studies (mid-trial rescue)”) and Veristat (“specialty CRO combining regulatory advisory, biostatistics/InStat, clinical operations, DCT, and clinical trial rescue”). Worldwide record · Veristat record.
- Pass-through costs & change orders
- Direct third-party trial expenses (investigator site grants, central labs, travel, IRB fees) billed outside CRO management fees, and contract amendments triggered when protocol scope or timelines shift.